Marshall Wace, LLP Adc Therapeutics Sa Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.66 - $5.29 $367,515 - $1.17 Million	221,395 Added 1013.34%	243,243 $1.09 Million
Q4 2023 Feb 14, 2024	SELL	$0.47 - $1.79 $195,907 - $746,116	-416,825 Reduced 95.02%	21,848 $36,000
Q3 2023 Nov 14, 2023	BUY	$0.72 - $2.37 $53,002 - $174,467	73,615 Added 20.17%	438,673 $394,000
Q2 2023 Aug 14, 2023	BUY	$1.9 - $2.66 $394,020 - $551,628	207,379 Added 131.52%	365,058 $784,000
Q1 2023 May 15, 2023	BUY	$1.92 - $5.45 $302,743 - $859,350	157,679 New	157,679 $307,000
Q1 2021 May 17, 2021	SELL	$22.75 - $34.05 $1.36 Million - $2.03 Million	-59,567 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$25.26 - $38.02 $3.44 Million - $5.17 Million	-136,085 Reduced 69.55%	59,567 $1.91 Million
Q3 2020 Nov 16, 2020	BUY	$32.87 - $51.05 $6.43 Million - $9.99 Million	195,652 New	195,652 $6.46 Million

55.1M

82.7K

31.5K

Ticker ADCT
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,645,296
Market Cap $172M
Description
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.